We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Mobile Platform Offers Patients Ultrafast Genetic Diagnosis

By LabMedica International staff writers
Posted on 01 Jan 2024
Print article
Image: The Genomtec ID mobile platform for genetic diagnostics (Photo courtesy of Genomtec SA)
Image: The Genomtec ID mobile platform for genetic diagnostics (Photo courtesy of Genomtec SA)

Molecular diagnostics traditionally requires knowledge of handling complex equipment and sample preparation. Now, a simple mobile platform for genetic diagnostics that is currently under development can be handled by healthcare professionals without any laboratory training.

Genomtec SA (Wrocław, Poland) is developing its flagship technological solution named Genomtec ID platform which will offer patients ultrafast mobile genetic diagnosis. The Genomtec ID platform is designed to facilitate diagnostic procedures on-site, including locations like public clinics, consulting rooms, hospitals, pharmacies, and emergency wards, eliminating the necessity for complex, time-consuming lab operations. The technology at the heart of Genomtec ID is the patented Streamlined Nucleic Acid Amplification Technology (SNAAT). This innovation ensures precise pathogen identification within 15 minutes, making it a rapid diagnostic solution. The Genomtec ID system combines the LAMP (loop-mediated isothermal amplification) method with microfluidics and a contactless photonic heating system. This integration allows for simultaneous isolation, purification, concentration, amplification, and detection of specific DNA or RNA fragments of pathogens, significantly speeding up the process while ensuring accuracy on par with or superior to conventional lab-based PCR methods.

One of the standout features of the SNAAT method is its capability for multiplexing, allowing for the simultaneous detection of multiple diagnostic targets on a microfluidic card. This means a single test can identify up to five pathogens at once. The use of a passive microfluidic card, devoid of embedded electronics or electric parts, for nucleic acid isolation, purification, and concentration, not only enhances the detection threshold for target nucleic acids but also reduces the manufacturing costs of disposable reaction cards. The robust diagnostic parameters offered by SNAAT, including sensitivity, specificity, and repeatability, are largely due to its resistance to common inhibitors found in biological samples like blood or drugs. This resistance makes SNAAT an innovative and reliable technology for point-of-care care testing (POCT), promising a new era of convenient and rapid diagnostics accessible to a broader range of healthcare settings.

Related Links:
Genomtec SA

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.